← Human Trials & Peer-Reviewed Studies
A Study of a Novel Precision Medicine Approach For Obesity
Plain-language guide to NCT06814938: phase 4 randomized trial of Semaglutide, 135 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06814938
- Phase
- phase 4
- Status
- active, not recruiting
- Start
- 2025-02-21
- Completion (planned or actual)
- 2027-12
- Participants
- 135 (estimated)
- Design
- randomized, triple-blind, treatment
- Conditions studied
- Obesity
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 4) is built around Semaglutide.
It had two arms (groups): Semaglutide Group (experimental) and Placebo Group (placebo comparator).
Subjects will take semaglutide weekly for 24 weeks.
Subjects will take placebo weekly for 24 weeks.
The registry classes the interventions as drug.
Who Took Part
Enrollment: 135 planned participants were the target.
It was open to people of any sex aged from 18 years up to 65 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
The full record lists 0 inclusion and 9 exclusion criteria; among the exclusions: history of bariatric surgery including lap band and bariatric endoscopy; any contraindication to fda-approved glp1r agonists; A person who is pregnant or wanting to become pregnant.
How the Study Was Run
It was run as a randomized, parallel-group and triple-blind study.
Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.
The Semaglutide group and the comparison group ran side by side rather than switching.
As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.
Those kept unaware of assignments: participant, care provider and investigator.
It started in 2025-02-21 with completion listed for 2027-12.
It ran at 2 sites in United States (2).
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: Change in Total Body Weight at 24 weeks (time frame: Baseline, 24 weeks).
It also tracked 7 secondary outcomes, for example Change in Total Body Weight at 3 months, Change in Total Body Weight at 6 months and Change in Waist Circumference.
What This Means in Plain Language
Put simply, this is a phase 4, randomized trial of Semaglutide in 135 people.
Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.